Atara Biotherapeutics, INC Form 4 insider transactions

Atara Biotherapeutics' CEO, AnhCo Nguyen, sold 3,331 shares of common stock on March 3, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Eric J. Hyllengren, EVP, CFO and COO of Atara Biotherapeutics, sold 1,211 shares of common stock on March 3, 2025, to cover tax obligations related to vesting restricted stock units.

Jill Henrich, EVP, Chief Regulatory Officer of Atara Biotherapeutics, sold 1,059 shares of common stock on March 3, 2025, to cover tax obligations related to vesting restricted stock units.

Eric J. Hyllengren, EVP, CFO and COO of Atara Biotherapeutics, was granted 34,050 restricted stock units on January 27, 2025, according to a Form 4 filing with the SEC.

Jill Henrich, EVP and Chief Regulatory Officer at Atara Biotherapeutics, sold 1,000 shares of common stock to cover tax obligations related to vesting restricted stock units.

Eric J. Hyllengren, EVP, CFO and COO of Atara Biotherapeutics, sold 1,364 shares of common stock to cover tax obligations related to vesting restricted stock units.

Atara Biotherapeutics CEO, AnhCo Nguyen, sold 1,664 shares of common stock at an average price of $11.198 to cover tax obligations related to vesting restricted stock units.

Atara Biotherapeutics' CEO, AnhCo Nguyen, acquired 45,000 shares of common stock on September 9, 2024, and disposed of 79,118 shares.

Atara Biotherapeutics CEO Pascal Touchon sold shares to cover tax withholding obligations related to vesting restricted stock units.

AnhCo Nguyen, EVP, Chief Sci. & Tech Officer of Atara Biotherapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

EVP and Chief Legal Officer of Atara Biotherapeutics, Amar Murugan, sold shares to cover tax withholding obligations related to vested restricted stock units.

Eric J. Hyllengren, CFO of Atara Biotherapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Jill Henrich, EVP at Atara Biotherapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Pascal Touchon, CEO of Atara Biotherapeutics, reports the cancellation of employee stock options and a forthcoming cash payment of $100 in exchange.

Atara Biotherapeutics CEO Pascal Touchon sold 81,506 shares of common stock on May 16, 2024, at a price of $0.617 per share to cover tax withholding obligations related to vesting restricted stock units.

AnhCo Nguyen, EVP, Chief Sci. & Tech Officer of Atara Biotherapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Amar Murugan, EVP and Chief Legal Officer of Atara Biotherapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Eric J. Hyllengren, EVP and CFO of Atara Biotherapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Jill Henrich, EVP at Atara Biotherapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Director Matthew K Fust reports acquiring 150,000 shares of Atara Biotherapeutics common stock and disposing of an unspecified amount.

Director William K. Heiden acquired 150,000 shares of Atara Biotherapeutics common stock on March 31, 2024.

Director Maria Grazia Roncarolo acquired 150,000 shares of Atara Biotherapeutics common stock on March 31, 2024, as reported in a Form 4 filing.

Director Carol Gallagher acquired 150,000 shares of Atara Biotherapeutics common stock on March 31, 2024, and also reports an additional 20,190 shares previously omitted.

Director Ameet Mallik of Atara Biotherapeutics acquired 150,000 shares of restricted stock on March 31, 2024, which will vest at the company's 2025 annual meeting.

Atara Biotherapeutics CEO Pascal Touchon sold shares of common stock on March 4, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

AnhCo Nguyen, EVP, Chief Sci. & Tech Officer of Atara Biotherapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Amar Murugan, EVP, Chief Legal Officer of Atara Biotherapeutics, sold 10,044 shares of common stock on March 4, 2024, to cover tax withholding obligations.

Eric J. Hyllengren, EVP and CFO of Atara Biotherapeutics, sold shares of common stock to satisfy tax withholding obligations related to vesting restricted stock units.

Jill Henrich, EVP at Atara Biotherapeutics, sold shares to cover tax obligations related to vesting restricted stock units.